Search

Your search keyword '"Science of Turin Health Agency [Turin, Italy] (City of the Health)"' showing total 3 results
Start Over Author "Science of Turin Health Agency [Turin, Italy] (City of the Health)"
3 results on '"Science of Turin Health Agency [Turin, Italy] (City of the Health)"'

1. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Brad H. Rovin, Dawn J. Caster, Daniel C. Cattran, Keisha L. Gibson, Jonathan J. Hogan, Marcus J. Moeller, Dario Roccatello, Michael Cheung, David C. Wheeler, Wolfgang C. Winkelmayer, Jürgen Floege, Sharon G. Adler, Charles E. Alpers, Isabelle Ayoub, Arvind Bagga, Sean J. Barbour, Jonathan Barratt, Daniel T.M. Chan, Anthony Chang, Jason Chon Jun Choo, H. Terence Cook, Rosanna Coppo, Fernando C. Fervenza, Agnes B. Fogo, Jonathan G. Fox, Richard J. Glassock, David Harris, Elisabeth M. Hodson, Elion Hoxha, Kunitoshi Iseki, J. Charles Jennette, Vivekanand Jha, David W. Johnson, Shinya Kaname, Ritsuko Katafuchi, A. Richard Kitching, Richard A. Lafayette, Philip K.T. Li, Adrian Liew, Jicheng Lv, Ana Malvar, Shoichi Maruyama, Juan Manuel Mejía-Vilet, Chi Chiu Mok, Patrick H. Nachman, Carla M. Nester, Eisei Noiri, Michelle M. O'Shaughnessy, Seza Özen, Samir M. Parikh, Hyeong-Cheon Park, Chen Au Peh, William F. Pendergraft, Matthew C. Pickering, Evangéline Pillebout, Jai Radhakrishnan, Manish Rathi, Pierre Ronco, William E. Smoyer, Sydney C.W. Tang, Vladimír Tesař, Joshua M. Thurman, Hernán Trimarchi, Marina Vivarelli, Giles D. Walters, Angela Yee-Moon Wang, Scott E. Wenderfer, Jack F.M. Wetzels, Baylor College of Medicine (BCM), Baylor University, Division of Nephrology, Rheinisch-Westfälische Technische Hochschule Aachen (RWTH), Department of Pediatrics, Division of Pediatric Nephrology and Genetics, All India Institute of Medical Sciences, University of British Columbia (UBC), Science of Turin Health Agency [Turin, Italy] (City of the Health), Regina Margherita University Children's Hospital [Turin, Italy], Mayo Clinic [Rochester], University College of London [London] (UCL), Molecular Otolaryngology and Renal Research Laboratories [Iowa City, IA, USA] (Carver College of Medicine), University of Iowa [Iowa City]-Carver College of Medicine, University of Iowa, Centre for Complement and Inflammation Research [London, UK] (Department of Medicine), Imperial College London, Service de rhumatologie, CHU Bordeaux [Bordeaux], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Colorado [Denver], Department of Medicine, The University of Hong Kong (HKU), Department of Nephrology [Nijmegen, The Netherlands], and Radboud University Medical Centre [Nijmegen, The Netherlands]

Subjects
0301 basic medicine, Nephrology, medicine.medical_specialty, membranoproliferative glomerulonephritis, Consensus Development Conferences as Topic, 030232 urology & nephrology, Lupus nephritis, Paraproteinemias, Context (language use), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, anti-neutrophil cytoplasmic antibody–associated vasculitis, 03 medical and health sciences, 0302 clinical medicine, Glomerulonephritis, Risk Factors, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Internal medicine, Membranoproliferative glomerulonephritis, medicine, Humans, Minimal change disease, C3 glomerulopathy, Genetic Testing, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, KDIGO, lupus nephritis, business.industry, Podocytes, Nephrosis, Lipoid, monoclonal gammopathies of renal significance, Guideline, medicine.disease, focal and segmental glomerulosclerosis, 3. Good health, minimal change disease, 030104 developmental biology, Treatment Outcome, Practice Guidelines as Topic, Disease Progression, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business, Biomarkers, Kidney disease, Glomerular Filtration Rate
Abstract

Contains fulltext : 203024.pdf (Publisher’s version ) (Open Access) In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.

Published
2019
Full Text
View/download PDF

2. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Jürgen Floege, Sean J. Barbour, Daniel C. Cattran, Jonathan J. Hogan, Patrick H. Nachman, Sydney C.W. Tang, Jack F.M. Wetzels, Michael Cheung, David C. Wheeler, Wolfgang C. Winkelmayer, Brad H. Rovin, Sharon G. Adler, Charles E. Alpers, Isabelle Ayoub, Arvind Bagga, Jonathan Barratt, Dawn J. Caster, Daniel T.M. Chan, Anthony Chang, Jason Chon Jun Choo, H. Terence Cook, Rosanna Coppo, Fernando C. Fervenza, Agnes B. Fogo, Jonathan G. Fox, Keisha L. Gibson, Richard J. Glassock, David Harris, Elisabeth M. Hodson, Elion Hoxha, Kunitoshi Iseki, J. Charles Jennette, Vivekanand Jha, David W. Johnson, Shinya Kaname, Ritsuko Katafuchi, A. Richard Kitching, Richard A. Lafayette, Philip K.T. Li, Adrian Liew, Jicheng Lv, Ana Malvar, Shoichi Maruyama, Juan Manuel Mejía-Vilet, Marcus J. Moeller, Chi Chiu Mok, Carla M. Nester, Eisei Noiri, Michelle M. O'Shaughnessy, Seza Özen, Samir M. Parikh, Hyeong-Cheon Park, Chen Au Peh, William F. Pendergraft, Matthew C. Pickering, Evangéline Pillebout, Jai Radhakrishnan, Manish Rathi, Dario Roccatello, Pierre Ronco, William E. Smoyer, Vladimír Tesař, Joshua M. Thurman, Hernán Trimarchi, Marina Vivarelli, Giles D. Walters, Angela Yee-Moon Wang, Scott E. Wenderfer, Division of Nephrology, Rheinisch-Westfälische Technische Hochschule Aachen (RWTH), University of British Columbia (UBC), Department of Nephrology [Nijmegen, The Netherlands], Radboud University Medical Centre [Nijmegen, The Netherlands], Baylor College of Medicine (BCM), Baylor University, Department of Pediatrics, Division of Pediatric Nephrology and Genetics, All India Institute of Medical Sciences, Science of Turin Health Agency [Turin, Italy] (City of the Health), Regina Margherita University Children's Hospital [Turin, Italy], Mayo Clinic [Rochester], University College of London [London] (UCL), Molecular Otolaryngology and Renal Research Laboratories [Iowa City, IA, USA] (Carver College of Medicine), University of Iowa [Iowa City]-Carver College of Medicine, University of Iowa, Centre for Complement and Inflammation Research [London, UK] (Department of Medicine), Imperial College London, Service de rhumatologie, CHU Bordeaux [Bordeaux], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Colorado [Denver], Department of Medicine, and The University of Hong Kong (HKU)

Subjects
0301 basic medicine, medicine.medical_specialty, Biopsy, Consensus Development Conferences as Topic, Kidney Glomerulus, 030232 urology & nephrology, Glomerulonephritis, Membranous, Nephropathy, 03 medical and health sciences, 0302 clinical medicine, Membranous nephropathy, Risk Factors, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], medicine, Humans, Glomerular disease, Renal Insufficiency, Chronic, Intensive care medicine, Glomerular diseases, ComputingMilieux_MISCELLANEOUS, Proteinuria, business.industry, Nephrosis, Lipoid, Glomerulonephritis, IGA, Guideline, medicine.disease, 3. Good health, 030104 developmental biology, Treatment Outcome, Nephrology, Practice Guidelines as Topic, Disease Progression, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], medicine.symptom, business, Kidney disease, Glomerular Filtration Rate
Abstract

Contains fulltext : 202673.pdf (Publisher’s version ) (Open Access) The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.

Published
2019
Full Text
View/download PDF

3. An international consensus approach to the management of atypical hemolytic uremic syndrome in children

Author

Daniel Landau, Magdalena Riedl, Chantal Loirat, Marina Vivarelli, Anne Laure Lapeyraque, Rosanna Coppo, Martin Bitzan, Sally Johnson, Anna Bjerre, Craig B. Langman, Francesco Emma, Véronique Frémeaux-Bacchi, Diana Karpman, Christoph Licht, Carmine Pecoraro, Gema Ariceta, Nicole C. A. J. van de Kar, Nesrin Besbas, Johan Vande Walle, Carla M. Nester, Fadi Fakhouri, Service de Néphrologie pédiatrique [Hôpital Robert Debré, Paris], Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Département de néphrologie et d'immunologie [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Pediatric Nephrology [Barcelona, Spain] (Vall d’Hebron Hospital), Universitat Autònoma de Barcelona (UAB)-Vall d'Hebron University Hospital [Barcelona], Department of Pediatric Nephrology [Ankara, Turkey] ( Faculty of Medicine), Hacettepe University = Hacettepe Üniversitesi, Division of Nephrology [Montreal, Canada] (Montreal Children’s Hospital), Montreal Children's Hospital, McGill University Health Center [Montreal] (MUHC)-McGill University Health Center [Montreal] (MUHC), Department of Pediatrics [Oslo, Norway], Oslo University Hospital [Oslo], Science of Turin Health Agency [Turin, Italy] (City of the Health), Regina Margherita University Children's Hospital [Turin, Italy], Bambino Gesù Children’s Hospital [Rome, Italy], Department of Paediatric Nephrology [Newcastle Upon Tyne, UK], Great North Children’s Hospital [Newcastle Upon Tyne, UK], Department of Pediatrics [Lund, Sweden] (Clinical Sciences), Lund University [Lund], Soroka University Medical Center [Beer Sheva, Israel], Ann & Robert H. Lurie Children's Hospital of Chicago, Service de Néphrologie [Montréal, Canada] (Département de Pédiatrie), Université de Montréal (UdeM), The Hospital for sick children [Toronto] (SickKids), the Stead Family Department of Pediatrics [Iowa City, Iowa, USA] (Departments of Internal Medicine), University of Iowa [Iowa City], Santobono Children’s Hospital [Naples, Italy], Department of Pediatrics [Innsbruck, Austria], Innsbruck Medical University [Austria] (IMU), Department of Pediatric Nephrology [Nijmegen, The Netherlands] ( Amalia Children’s Hospital), Radboud University Medical Center [Nijmegen]-Amalia Children’s Hospital [Nijmegen, The Netherlands], Ghent University Hospital [Ghent, Belgium], Immunologie et Cancérologie Intégratives (CRC - Inserm U1138), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Le Bihan, Sylvie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré, and Innsbruck Medical University = Medizinische Universität Innsbruck (IMU)

Subjects
Anti-factor H antibody, Nephrology, Atypical hemolytic uremic syndrome, International Cooperation, 030232 urology & nephrology, Disease, 030204 cardiovascular system & hematology, Kidney transplantation, 0302 clinical medicine, Risk Factors, Hemolytic uremic syndrome, Cooperative Behavior, Child, Complement Activation, Children, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Age Factors, Eculizumab, Combined Modality Therapy, 3. Good health, Treatment Outcome, Child, Preschool, Combined liver–kidney transplantation, Drug Monitoring, medicine.drug, medicine.medical_specialty, Consensus, Thrombotic microangiopathy, Adolescent, Complement, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Therapeutic approach, Monitoring, Immunologic, Predictive Value of Tests, Internal medicine, medicine, Humans, Immunologic Factors, Plasma exchange, Intensive care medicine, business.industry, Patient Selection, Infant, Newborn, Infant, medicine.disease, Liver Transplantation, Transplantation, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Pediatrics, Perinatology and Child Health, Plasma infusion, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Item does not contain fulltext Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g., using an anti-C5 antibody (eculizumab). We review treatment and patient management issues related to this therapeutic approach. We present consensus clinical practice recommendations generated by HUS International, an international expert group of clinicians and basic scientists with a focused interest in HUS. We aim to address the following questions of high relevance to daily clinical practice: Which complement investigations should be done and when? What is the importance of anti-factor H antibody detection? Who should be treated with eculizumab? Is plasma exchange therapy still needed? When should eculizumab therapy be initiated? How and when should complement blockade be monitored? Can the approved treatment schedule be modified? What approach should be taken to kidney and/or combined liver-kidney transplantation? How should we limit the risk of meningococcal infection under complement blockade therapy? A pressing question today regards the treatment duration. We discuss the need for prospective studies to establish evidence-based criteria for the continuation or cessation of anticomplement therapy in patients with and without identified complement mutations.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results